Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2024-02, Vol.30 (2), p.338-341
Hauptverfasser:	Levine, Bruce L., Pasquini, Marcelo C., Connolly, John E., Porter, David L., Gustafson, Michael P., Boelens, Jaap J., Horwitz, Edwin M., Grupp, Stephan A., Maus, Marcela V., Locke, Frederick L., Ciceri, Fabio, Ruggeri, Annalisa, Snowden, John, Heslop, Helen E., Mackall, Crystal L., June, Carl H., Sureda, Anna M., Perales, Miguel-Angel
Format:	Artikel
Sprache:	eng
Schlagworte:	631/250/251 631/67/1059/2325 Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Cell therapy Cell- and Tissue-Based Therapy Chemotherapy Comment FDA approval Gene therapy Hematologic Neoplasms - pathology Humans Immunotherapy Immunotherapy, Adoptive - adverse effects Infectious Diseases Leukemia Lymphocytes Lymphocytes T Lymphoma Lymphoma, B-Cell - therapy Malignancy Metabolic Diseases Molecular Medicine Mutation Neurosciences Receptors, Chimeric Antigen Sickle cell disease Stem cells T cell receptors Transplants & implants Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.
ISSN:	1078-8956 1546-170X 1546-170X
DOI:	10.1038/s41591-023-02767-w